Atlantic(ATLC), a new twist to antisense Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Atlantic(ATLC), a new twist to antisense

ATLC 58.29

-2.2%

3:07 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Greg Rich who wrote (9)	10/26/1999 4:00:00 PM
From: notyet	Read Replies (1) of 22

From the latest 10-KSB 'The company believes that these companies are potential partners rather than competitors as data generated to date shows that the 2-5A Chimeric Antisense Technology can potentially be used to enhance the efficacy of other antisense oligonucleotides, or alternatively be capable of independently demonstrating superior activity against selected disease targets being pursued by other companies. It is also becoming increasingly apparent to the scientific community that the more sophisticated,stabilizing backbone technologies being pursued by most companies are less active in their ability to recruit RNaseH, a key RNA-degredative enzyme. The 2-5A antisense technology appears to be highly compatible with newer backbones, without compromising the ability to recruit and activate RNaseL. No other solutions to this apparent dilemma are currently known.' ATLC is pretty forthright. If above is true ATLC has the best antisense technology. I own both ISIP and ATLC. ISIP is way ahead but if ATLC can finance their program until they persuade some larger company to strike a deal they might leave the rest of the antisense pack way behind.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next